Preliminary findings from a phase I, open-label, dose-finding study of SNB-101 in patients with advanced solid tumors

被引:0
|
作者
Sang, Y. B. [1 ]
Kim, Y. [1 ]
Lee, M. A. [2 ]
Rha, S. Y. [3 ]
Jung, M. [3 ]
Lee, C-K. [3 ]
Park, Y. H. [4 ]
Heo, D. [4 ]
Kim, A. [4 ]
Kim, J. [4 ]
Kim, J-H. [1 ]
机构
[1] CHA Univ, Med Oncol, CHA Bundang Med Ctr, Seongnam, South Korea
[2] Catholic Univ Korea, Seoul St Marys Hosp, Med Oncol, Seoul, South Korea
[3] Yonsei Univ Hlth Syst, Yonsei Canc Ctr, Med Oncol, Seoul, South Korea
[4] SN BioSci, Med Oncol, Seongnam, South Korea
关键词
D O I
10.1016/j.annonc.2023.09.1863
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
677P
引用
收藏
页码:S474 / S474
页数:1
相关论文
共 50 条
  • [41] A phase I open-label study investigating the disposition of [14C]-cabazitaxel in patients with advanced solid tumors
    Ridoux, Laurence
    Semiond, Dorothee R.
    Vincent, Carine
    Fontaine, Helene
    Mauriac, Christine
    Sanderink, Ger-Jan
    Oprea, Corina
    Kelly, Lindsay
    Clive, Sally
    ANTI-CANCER DRUGS, 2015, 26 (03) : 350 - 358
  • [42] A Phase I, open-label study investigating the disposition of [14C]-cabazitaxel in patients with advanced solid tumors
    Ridoux, Laurence
    Semiond, Dorothee
    Vincent, Carine
    Fontaine, Helene
    Mauriac, Christine
    Sanderink, Gerard
    Oprea, Corina
    Clive, Sally
    CANCER RESEARCH, 2012, 72
  • [43] An open-label, multicenter, phase I study of ATG-022 in patients with advanced/metastatic solid tumors (CLINCH).
    Bishnoi, Sarwan
    Cao, Dan
    Mendis, Shehara Ramyalini
    Coward, Jim
    Zhao, Jun
    Xie, Hui
    Zheng, Li
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [44] A phase I open-label study of FGFR/VEGFR inhibitor FH-2001 in patients with advanced solid tumors
    Song, Zhengbo
    Hui, Ai-min
    Wu, Zhuli
    Liu, Huilong
    Cheng, Xiangdong
    CANCER RESEARCH, 2022, 82 (12)
  • [45] Ifosfamide and irinotecan in solid tumors:: A phase I dose-finding trial
    Moyano, AJ
    Seguí, MA
    Abad, T
    Urruticoechea, L
    López, JLG
    Nogué, M
    Dominguez, MS
    Balcells, M
    Dorado, JF
    SEMINARS IN ONCOLOGY, 2000, 27 (01) : 3 - 7
  • [46] A FIRST-IN-HUMAN, MULTICENTER, PHASE 1/2, OPEN-LABEL STUDY OF XTX101 IN PATIENTS WITH ADVANCED SOLID TUMORS
    Powderly, John
    Norman, Teleen
    Duncan, Meghan
    Huber, Martin
    O'Neil, Jennifer
    Patel, Ekta
    Vandross, Andrae
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A549 - A549
  • [47] A MULTICENTER OPEN-LABEL PHASE I/LB STUDY OF SO-C101 AS MONOTHERAPY AND IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH SELECTED ADVANCED/METASTATIC SOLID TUMORS
    Marabelle, Aurelien
    Champiat, Stephane
    Garralda, Elena
    Hernando, Alberto
    Janku, Filip
    Raina, Anjali
    Sachse, Richard
    Bechard, David
    Krasnopolskaya, Inna
    Ferrara, Stefano
    LoRusso, Patricia
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A483 - A483
  • [48] Sunitinib in combination with gemcitabine for advanced solid tumours: a phase I dose-finding study
    M D Michaelson
    A X Zhu
    D P Ryan
    D F McDermott
    G I Shapiro
    L Tye
    I Chen
    P Stephenson
    S Patyna
    A Ruiz-Garcia
    A B Schwarzberg
    British Journal of Cancer, 2013, 108 : 1393 - 1401
  • [49] Epacadostat plus durvalumab in patients with advanced solid tumors: preliminary results of the ongoing, open-label, phase I/II ECHO-203 study
    Naing, Aung
    Powderly, John D.
    Falchook, Gerald
    Creelan, Benjamin
    Nemunaitis, John
    Lutzky, Jose
    Diab, Adi
    Wang, Judy S.
    Laing, Naomi
    Niewood, Michelle
    Gong, Xiaohua
    Zhou, Gongfu
    Patel, Manish
    CANCER RESEARCH, 2018, 78 (13)
  • [50] Sunitinib in combination with gemcitabine for advanced solid tumours: a phase I dose-finding study
    Michaelson, M. D.
    Zhu, A. X.
    Ryan, D. P.
    McDermott, D. F.
    Shapiro, G. I.
    Tye, L.
    Chen, I.
    Stephenson, P.
    Patyna, S.
    Ruiz-Garcia, A.
    Schwarzberg, A. B.
    BRITISH JOURNAL OF CANCER, 2013, 108 (07) : 1393 - 1401